- Home
- KIND vs TRVI Comparison
KIND vs TRVI Comparison
Compare KIND & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIND
- TRVI
- Stock Information
- Founded
- KIND 2011
- TRVI 2011
- Country
- KIND United States
- TRVI United States
- Employees
- KIND N/A
- TRVI N/A
- Industry
- KIND Computer Software: Programming Data Processing
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- KIND Technology
- TRVI Health Care
- Exchange
- KIND Nasdaq
- TRVI Nasdaq
- Market Cap
- KIND 608.3M
- TRVI 725.7M
- IPO Year
- KIND N/A
- TRVI 2019
- Fundamental
- Price
- KIND $1.88
- TRVI $7.87
- Analyst Decision
- KIND Buy
- TRVI Strong Buy
- Analyst Count
- KIND 4
- TRVI 9
- Target Price
- KIND $2.56
- TRVI $19.94
- AVG Volume (30 Days)
- KIND 2.3M
- TRVI 1.9M
- Earning Date
- KIND 08-07-2025
- TRVI 08-07-2025
- Dividend Yield
- KIND N/A
- TRVI N/A
- EPS Growth
- KIND N/A
- TRVI N/A
- EPS
- KIND N/A
- TRVI N/A
- Revenue
- KIND $248,306,000.00
- TRVI N/A
- Revenue This Year
- KIND $1.66
- TRVI N/A
- Revenue Next Year
- KIND $10.87
- TRVI N/A
- P/E Ratio
- KIND N/A
- TRVI N/A
- Revenue Growth
- KIND 12.01
- TRVI N/A
- 52 Week Low
- KIND $1.32
- TRVI $2.36
- 52 Week High
- KIND $3.00
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- KIND 60.19
- TRVI 74.32
- Support Level
- KIND $1.63
- TRVI $6.67
- Resistance Level
- KIND $2.50
- TRVI $8.11
- Average True Range (ATR)
- KIND 0.13
- TRVI 0.41
- MACD
- KIND 0.02
- TRVI 0.17
- Stochastic Oscillator
- KIND 31.11
- TRVI 89.66
About KIND Nextdoor Holdings Inc.
Nextdoor Holdings Inc is the platform to connect to the neighborhoods. The purpose is to cultivate a kinder world where everyone has a neighborhood. Neighbors around the world turn to Nextdoor daily to receive trusted information, give and get help, get things done, and build real-world connections with nearby neighbors, businesses, and public services. It offers a comprehensive suite of advertising solutions designed to deliver exceptional value for businesses of all size.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.